A suspected plague death in Russia has renewed attention on the rare infection. Here's how to spot pneumonic plague and which antibiotics the CDC recommends.
|Articles|July 19, 2022
Daily Medication Pearl: Dalbavancin (Dalvance)
Author(s)Saro Arakelians, PharmD
Dalbavancin (Dalvance) is indicated for acute bacterial skin and skin structure infections caused by designated susceptible strains of Gram-positive microorganisms.
Advertisement
Medication Pearl of the Day: Dalvance (dalbavancin)
Indication: Dalbavancin (Dalvance) is indicated for acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible strains of Gram-positive microorganisms.
Insight:
- Dosing: Two-dose regimen 1000 mg followed 1 week later by 500 mg.
- Dosage forms: For injection 500 mg of lyophilized powder in a single-use vial for reconstitution.
- Adverse events: The most common adverse reactions in patients treated with dalbavancin were nausea (5.5%), headache (4.7%), and diarrhea.
- Mechanism of action: Dalbavancin, a semisynthetic lipoglycopeptide, interferes with cell wall synthesis by binding to the D-alanyl-D-alanine terminus of the stem pentapeptide in nascent cell wall peptidoglycan, thus preventing cross-linking.
Source:
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
SubscribeAdvertisement
Related to this article
Tor Härnqvist, MD, discusses immune testing after invasive pneumococcal disease, serotype-informed vaccine selection, and pharmacists' role in supporting patients on immunoglobulin therapy.
Invasive pneumococcal disease may be the first sign of undiagnosed blood cancers and antibody deficiencies in adults, a new study finds.
Growing evidence points to gallstones and cholecystitis as an underrecognized risk of GLP-1 RA therapy—pharmacists are well positioned to catch it early.
Investigational inhaled stem cells for COPD raise questions about lasting clinical benefit and the pharmacy controls needed to deliver a living-cell product through a nebulizer.
In an interview with Pharmacy Times, Abdulkader Rahmo, PhD, discusses investigational inhaled cell therapy for COPD, the evidence needed to establish lasting clinical benefit, and pharmacists’ potential role in its delivery.
A meta-analysis of 27 trials found 15% lower cardiovascular (CV) event risk per 10-mm Hg SBP reduction, with eGFR declines but no rise in kidney failure.
In an interview with Pharmacy Times, City of Hope researchers discuss a preclinical platform designed to redirect CAR T cells after infusion and how pharmacists could help bring this adaptable approach into clinical practice.
Advertisement
Advertisement